Saratov JOURNAL of Medical and Scientific Research

Levanov A.N.

Saratov State Medical University, Department of Pharmacology and Clinical Pharmacology, Post-graduate

Pharmacodynamic and pharmacoeconomic aspects of application of antihypertensive preparations of various groups in patients with arterial hypertension

Year: 2010, volume 6 Issue: №3 Pages: 504-510
Heading: Clinical Pharmacology Article type: Original article
Authors: Kurkina T.V., Svistunov А.А., Bogoslovskaya S.I., Klochkov V.A., Glybochko G.H., Shuldyakov V.A., Luchinina EM., Levanov A.N.
Organization: Saratov State Medical University, Saratov Regional Hospital for Veterans of Wars, Saratov Institute of Cardiology, Russia
Summary:

At the background of the therapy for 3 months with Perindopril, Telmisartan and Bisoprolol, the patients with arterial hypertension were noted to decrease systolic and diastolic arterial pressure. The preparations under investigation had different effects on electrolyte metabolism. Therapy with Telmisartan turned out to have the least effect on electrolyte metabolism. Microalbuminuria is a risk factor in patients with arterial hypertension and may influence on the basic blood electrolyte balance. Bisoprolol should be recommended as the most preferable therapy for arterial hypertension from the pharmacoeconomic point of view. In order to control morning systolic arterial pressure the preference should be given to Perindopril, while for controlling evening systolic arterial pressure the preference should be given to Telmisartan

AttachmentSize
201003_504_510.pdf330.03 KB

BETA-ADRENORECEPTORS GENETIC POLYMORPHISM CONNECTION WITH BETA-BLOKER THERAPY EFFICACY IN PATIENTS WITH CARDIOVASCULAR DISORDERS

Year: 2009, volume 5 Issue: №1 Pages: 41-44
Heading: Clinical Pharmacology Article type: Original article
Authors: A.N. Levanov, I.V. Ignatyev, D.A. Sychev, S.I. Bogoslovskaya, A.A. Svistunov
Organization: Saratov State Medical University, First Moscow State Medical University n.a. I.M. Sechenov, Institute of Clinical Pharmacology
Summary:

At present it is obvious that genetic peculiarities of patients are the major reason for individual differences in pharmacological responses to (?-adrenoblockers. Furthermore ADRB1 gene polymorphism is responsible for the efficiency of (?-adrenoblockers. Thus, a real prospect exists for an individualized approach to administration of (?-adrenoblockers and selection of dosage based on patient’s genotype, which must undoubtedly increase efficiency of the administered therapy. Reviewfocuses on gene polymorphism responsible for (?-adrenoblockers pharmacodynamics and on the clinical significance of the polymorphism detection to individualize drug therapy based on patient’s genotype.

AttachmentSize
200901_041_044.pdf207.86 KB